Flumedroxone: Difference between revisions

	WikiDoc Resources for Flumedroxone
Articles
Most recent articles on Flumedroxone Most cited articles on Flumedroxone Review articles on Flumedroxone Articles on Flumedroxone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Flumedroxone Images of Flumedroxone Photos of Flumedroxone Podcasts & MP3s on Flumedroxone Videos on Flumedroxone
Evidence Based Medicine
Cochrane Collaboration on Flumedroxone Bandolier on Flumedroxone TRIP on Flumedroxone
Clinical Trials
Ongoing Trials on Flumedroxone at Clinical Trials.gov Trial results on Flumedroxone Clinical Trials on Flumedroxone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Flumedroxone NICE Guidance on Flumedroxone NHS PRODIGY Guidance FDA on Flumedroxone CDC on Flumedroxone
Books
Books on Flumedroxone
News
Flumedroxone in the news Be alerted to news on Flumedroxone News trends on Flumedroxone
Commentary
Blogs on Flumedroxone
Definitions
Definitions of Flumedroxone
Patient Resources / Community
Patient resources on Flumedroxone Discussion groups on Flumedroxone Patient Handouts on Flumedroxone Directions to Hospitals Treating Flumedroxone Risk calculators and risk factors for Flumedroxone
Healthcare Provider Resources
Symptoms of Flumedroxone Causes & Risk Factors for Flumedroxone Diagnostic studies for Flumedroxone Treatment of Flumedroxone
Continuing Medical Education (CME)
CME Programs on Flumedroxone
International
Flumedroxone en Espanol Flumedroxone en Francais
Business
Flumedroxone in the Marketplace Patents on Flumedroxone
Experimental / Informatics
List of terms related to Flumedroxone

Flumedroxone
Clinical data
Synonyms	(6S,10R,13S,17S)-17-acetyl-17-hydroxy-10,13-dimethyl-6-(trifluoromethyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Acetyloxy-6α-(trifluoromethyl)preg-4-ene-3,20-dione
ATC code	N02CB01 (WHO) ;
Identifiers
	IUPAC name (2R,8S,14S,15S)-14-acetyl-14-hydroxy-2,15-dimethyl-8-(trifluoromethyl)tetracyclo[8.7.0.02,7.011,15]heptadec-6-en-5-one;
CAS Number	987-18-8;
PubChem CID	71881;
ChemSpider	16736667;
UNII	K80185F39X;
ChEMBL	ChEMBL2104932;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C22H29F3O3
Molar mass	398.459 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C(F)(F)F)C)O;
	InChI InChI=1S/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1; Key:CDZJOBWKHSYNMO-SCUQKFFVSA-N;
(verify)

VisualWikitext

Latest revision as of 21:03, 18 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Flumedroxone is a corticosteroid derivative used to treat migraines. In one study, the benefit was largely limited to women with headache associated with premenstrual syndrome.^[1]

References

↑ Bradley WG, Hudgson P, Foster JB, Newell DJ (August 1968). "Double-blind controlled trial of a micronized preparation of flumedroxone (Demigran) in prophylaxis of migraine". Br Med J. 3 (5617): 531–3. doi:10.1136/bmj.3.5617.531. PMC 1986487. PMID 4877801.

Template:Antimigraine preparations

Template:Analgesic-stub

[pmid4877801-1] Bradley WG, Hudgson P, Foster JB, Newell DJ (August 1968). "Double-blind controlled trial of a micronized preparation of flumedroxone (Demigran) in prophylaxis of migraine". Br Med J. 3 (5617): 531–3. doi:10.1136/bmj.3.5617.531. PMC 1986487. PMID 4877801.

[1]

@@ Line 1: / Line 1: @@
-__NOTOC__
+{{Drugbox
-{{Flumedroxone}}
+| verifiedrevid = 447816182
-{{CMG}}; {{AE}} {{PB}}
+| IUPAC_name = (2''R'',8''S'',14''S'',15''S'')-14-acetyl-14-hydroxy-2,15-dimethyl-8-(trifluoromethyl)tetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadec-6-en-5-one
+| image = Flumedroxone Wiki Str.png
-'''''For patient information about Flumedroxone, click [[Flumedroxone (patient information)|here]]'''''
+| alt = Skeletal formula of flumedroxone
-{{SB}}
+<!--Clinical data-->
+| tradename =
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
+| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
+| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
+| legal_status =
+| routes_of_administration =
-==Overview==
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
-==Category==
+<!--Identifiers-->
+| CAS_number = 987-18-8
+| ATC_prefix = N02
+| ATC_suffix = CB01
+| PubChem = 71881
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| ChEMBL = 2104932
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = K80185F39X
+|  ChemSpiderID = 16736667
-==FDA Package Insert==
+<!--Chemical data-->
+| C=22 | H=29 | F=3 | O=3
+| molecular_weight = 398.459 g/mol
+|  smiles = CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C(F)(F)F)C)O
+|  InChI = 1/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1
+|  InChIKey = CDZJOBWKHSYNMO-SCUQKFFVBJ
+|  StdInChI = 1S/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1
+|  StdInChIKey = CDZJOBWKHSYNMO-SCUQKFFVSA-N
-'''| [[Flumedroxone indications and usage|Indications and Usage]]'''
+| synonyms = <small>(6''S'',10''R'',13''S'',17''S'')-17-acetyl-17-hydroxy-10,13-dimethyl-6-(trifluoromethyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthren-3-one<br>17-Acetyloxy-6α-(trifluoromethyl)preg-4-ene-3,20-dione</small>
-'''| [[Flumedroxone dosage and administration|Dosage and Administration]]'''
+}}
-'''| [[Flumedroxone dosage forms and strengths|Dosage Forms and Strengths]]'''
+__NOTOC__
-'''| [[Flumedroxone contraindications|Contraindications]]'''
+{{SI}}
-'''| [[Flumedroxone warnings and precautions|Warnings and Precautions]]'''
+{{CMG}}
-'''| [[Flumedroxone adverse reactions|Adverse Reactions]]'''
+== Overview ==
-'''| [[Flumedroxone drug interactions|Drug Interactions]]'''
-'''| [[Flumedroxone use in specific populations|Use in Specific Populations]]'''
-'''| [[Flumedroxone overdosage|Overdosage]]'''
-'''| [[Flumedroxone description|Description]]'''
-'''| [[Flumedroxone clinical pharmacology|Clinical Pharmacology]]'''
-'''| [[Flumedroxone nonclinical toxicology|Nonclinical Toxicology]]'''
-'''| [[Flumedroxone clinical studies|Clinical Studies]]'''
-'''| [[Flumedroxone how supplied storage and handling|How Supplied/Storage and Handling]]'''
-'''| [[Flumedroxone patient counseling information|Patient Counseling Information]]'''
-'''| [[Flumedroxone labels and packages|Labels and Packages]]'''
-==Mechanism of Action==
+'''Flumedroxone''' is a [[corticosteroid]] derivative used to treat [[migraine]]s. In one study, the benefit was largely limited to women with headache associated with [[premenstrual syndrome]].<ref name="pmid4877801">{{cite journal |author=Bradley WG, Hudgson P, Foster JB, Newell DJ |title=Double-blind controlled trial of a micronized preparation of flumedroxone (Demigran) in prophylaxis of migraine |journal=Br Med J |volume=3 |issue=5617 |pages=531–3 |date=August 1968 |pmid=4877801 |pmc=1986487 |doi= 10.1136/bmj.3.5617.531|url=}}</ref>
 ==References==
+{{reflist|2}}
+{{Antimigraine preparations}}
+[[Category:drug]]
+[[Category:Steroids]]
+[[Category:Organofluorides]]
-{{Reflist|2}}
-[[Category:Cardiovascular Drugs]]
+{{analgesic-stub}}
-[[Category:Drugs]]

Flumedroxone: Difference between revisions

Latest revision as of 21:03, 18 August 2015

Overview

References

Navigation menu